Explore the latest in PCI, including evolving indications, technologies, and use of antiplatelet agents to maximize efficacy and safety.
This prespecified analysis of a randomized clinical trial assesses the safety and efficacy of ticagrelor vs prasugrel for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention.
This study provides a contemporary assessment of population-level trends in percutaneous coronary intervention use among all age groups, insurance payers, and hospital settings across 4 US states.
This subgroup analysis of a randomized clinical trial explores differences in outcomes by sex among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin after percutaneous coronary intervention.
This post hoc analysis of a randomized clinical trial applies the Academic Research Consortium for high bleeding risk trade-off model to the GLOBAL LEADERS trial population.
This cross-sectional study examines the readability, accuracy, content, quality, and suitability of online health information on coronary artery bypass grafting or percutaneous coronary intervention for patients.
This randomized clinical trial evaluates the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.
This cohort study compares the change in the rate of memory decline after coronary artery bypass grafting (CABG) vs percutaneous coronary intervention (PCI) in older adults.
This cohort study describes temporal trends and institutional variations of multivessel percutaneous coronary intervention use for ST-elevation myocardial infarction in the United States between 2009 and 2018.
This narrative review summarizes oral antiplatelet therapy and specifically addresses the effects of dual antiplatelet therapy for patients with acute coronary syndrome who have not taken anticoagulants.
This study investigates variation in site-specific risk-adjusted mortality rates of percutaneous coronary intervention for physicians practicing at multiple sites within New York State.
This prognostic study develops and validates models to predict the risks of major bleeding (Bleeding Academic Research Consortium types 3-5 bleeding) and myocardial infarction and/or stent thrombosis for individual patients at high bleeding risk.
This post hoc analysis of a randomized clinical trial studies the association of thrombus aspiration with outcomes among patients presenting with ST-segment elevation myocardial infarction based on time.
This Viewpoint summarizes the pathophysiology and clinical features of atherosclerotic plaque erosion as an underlying mechanism of acute coronary syndromes (ACS) distinct from plaque rupture and reviews evidence that antithrombotic therapy without PCI and stenting may be optimal treatment.
This cross-sectional study examines the demographic, clinical, and institutional characteristics as well as other features of users of hemodynamic support therapies after a percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock.
This cohort study assesses adherence to evidence-based fractional flow reserve (FFR) thresholds for percutaneous coronary intervention in Canada between 2013 and 2018, and associations of percutaneous coronary intervention with major adverse clinical outcomes for patients with FFR measures above and beneath ischemic thresholds.
This post hoc analysis of a randomized clinical trial evaluates the association of culprit lesion location with outcomes of culprit-lesion-only percutaneous coronary intervention with optional staged revascularization vs immediate multivessel percutaneous coronary intervention in patients with multivessel disease, myocardial infarction, and cardiogenic shock.
Customize your JAMA Network experience by selecting one or more topics from the list below.